In this article, new recommendations were made that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time). Hydroxychloroquine creatinine What does hydroxychloroquine do to your eyes Aralen contraindicaciones Hydroxychloroquine toxicity Disease Entity. Hydroxychloroquine Plaquenil and chloroquine cause ocular toxicity. Diagnosis. For retinopathy, patients should be asked about poor central vision. Management. At the first signs of retinal toxicity, hydroxychloroquine should be stopped. Hence, it is imperative that we become familiar with recognizing the spectrum of HVF and SD-OCT findings associated with Plaquenil retinal toxicity. Of note, SD-OCT, in combination with Humphrey visual field testing, is critical for the early detection of Plaquenil retinal toxicity. The American Academy of Ophthalmology has published several dosing and screening recommendations for hydroxychloroquine to avoid potential retinal toxicity, yet some patients still experience permanent vision loss resulting from hydroxychloroquine retinopathy due to improper dosing of the drug and improper screening. The previous AAO guideline recommended screening every 12 months. It has become fairly common practice for most rheumatologists to recommend that patients being treated with hydroxychloroquine be seen for formal visual field evaluation once or twice a year to monitor for retinal toxicity. Plaquenil retina toxicity Hydroxychloroquine-related retinal toxicity Rheumatology., How to Succeed in Plaquenil Screenings Hydroxychloroquine malaria prophylaxis doseChloroquine vs atovaquoneHydroxychloroquine 200 mg acetaminophen 400 mg Hydroxychloroquine sulfate HCQ, Plaquenil is an analogue of chloroquine CQ, an antimalarial agent, used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune disorders. Its use has been associated with severe retinal toxicity, requiring a discontinuation of therapy. Retinal toxicity associated with chronic exposure to.. Despite Plaquenil dosing recommendations, retinal toxicity.. Plaquenil Toxicity Screening - Retina Group of New York. The risk of a toxicity sharply increases after 5 years, with majority of cases of retinotoxicity occurring in patients that have had a cumulative dose exceeding 1000g of hydroxychloriquine Plaquenil. This level is reached in about 7 years with the most common daily dose of Plaquenil, 400 mg/day 200 bid. Although it is not possible to predict which patients will develop retinal toxicity, high-risk characteristics include the following daily dose greater than 400 mg or, in people of short stature, a daily dosage over 6.5 mg/kg ideal body weight or total cumulative dose of more than 1,000 g. Plaquenil-induced toxicity usually will not occur before five years of taking the drug. “Eye damage due to Plaquenil is not common,” he says. “Rarely will anybody who has good vision and minimal symptoms develop loss of central vision or ability to read if annual screening is done and visual are symptoms reported as soon as they occur so the medication can be stopped if toxicity occurs.